Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
SolasCure logo — Transforming chronic wound care with a breakthrough wound th...

SolasCure

Transforming chronic wound care with a breakthrough wound therapeutic

Founded 2017 United Kingdom Cambridge, United Kingdom 17 employees Grant Total: $26.31M Biopharma, Biotechnology +1

General Information

Company Name SolasCure
Founded Year 2017
Location United Kingdom Cambridge, United Kingdom +1
Employees 17
Industries Biopharma, Biotechnology, Health Care
Funding Stage Grant
Social

Get notified when SolasCure moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About SolasCure

SolasCure is a UK-based startup dedicated to revolutionizing chronic wound care with its breakthrough enzymatic technology. The company's flagship product, Aurase Wound Gel, is designed to address the unmet needs in chronic wound care, catering to both hospitals, clinics, and homes. This product, comprised of tarumase, a highly-specific fibrinolytic enzyme isolated & cloned from maggot saliva in a hydrogel, aims to provide an easy-to-use, effective solution for wound debridement and preparation. Aurase Wound Gel has successfully completed Phase IIa trials, demonstrating its safety, effectiveness, and pain-free application. The company has received notable recognition and grants, such as the Biomedical Catalyst Grant from Innovate UK, the EIC Accelerator Grant from the European Innovation Council, and the Life Sciences Innovator award from the UK Department for Trade and Business. Furthermore, SolasCure is the winner of the 2019 URGO Mentorship Programme. Founded in 2017 as a spin-off from BRAIN Biotech AG, SolasCure has shown significant promise in the biopharma, biotechnology, and healthcare industries. With its headquarters in Cambridge, UK, the company is poised to make a significant impact in the field of chronic wound care. For more information, visit their website at www.solascure.com.

Taxonomy: biologics company, wound care, chronic wounds, biomimicry, evidence-based medicine, investigational product, debridement technology, healthcare professionals, outpatient care, home care, biotech company, bio-based solutions, innovation, biological diversity, enzyme technology

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1
Investor
20 Mar 2024
Series B •••••• 5
Investor
•••• •••• 		27 Mar 2023
Series A •••••• 4
Investor Investor
•••• •••• 		09 Aug 2021
Grant •••••• - 17 May 2021
Seed Round •••••• - 20 Aug 2018

FAQ About SolasCure

Transforming chronic wound care with a breakthrough wound therapeutic
SolasCure was founded in 2017.
SolasCure is headquartered in Cambridge, United Kingdom.
SolasCure operates in the following industries: Biopharma, Biotechnology, Health Care.
SolasCure has approximately 17 employees.
SolasCure has completed 5 funding rounds, raising a total of $26.31M. The latest funding stage is Grant.

We're actively collecting intelligence on SolasCure.

Track SolasCure to get notified

Don't just browse. Track.

Signal Tracker monitors SolasCure and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy